
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31627366</article-id><article-id pub-id-type="pmc">6836125</article-id><article-id pub-id-type="doi">10.3390/md17100588</article-id><article-id pub-id-type="publisher-id">marinedrugs-17-00588</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antiamoebic Activities of Indolocarbazole Metabolites Isolated from <italic>Streptomyces sanyensis</italic> Cultures</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cartuche</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-17-00588">1</xref><xref ref-type="aff" rid="af2-marinedrugs-17-00588">2</xref></contrib><contrib contrib-type="author"><name><surname>Reyes-Batlle</surname><given-names>Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00588">3</xref></contrib><contrib contrib-type="author"><name><surname>Sifaoui</surname><given-names>Ines</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00588">3</xref></contrib><contrib contrib-type="author"><name><surname>Arberas-Jim&#x000e9;nez</surname><given-names>I&#x000f1;igo</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00588">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6233-8224</contrib-id><name><surname>Pi&#x000f1;ero</surname><given-names>Jos&#x000e9; E.</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00588">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0805-8317</contrib-id><name><surname>Fern&#x000e1;ndez</surname><given-names>Jos&#x000e9; J.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-17-00588">1</xref><xref ref-type="aff" rid="af4-marinedrugs-17-00588">4</xref></contrib><contrib contrib-type="author"><name><surname>Lorenzo-Morales</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00588">3</xref><xref rid="c1-marinedrugs-17-00588" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8886-7519</contrib-id><name><surname>D&#x000ed;az-Marrero</surname><given-names>Ana R.</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-17-00588">1</xref><xref rid="c1-marinedrugs-17-00588" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-marinedrugs-17-00588"><label>1</label>Instituto Universitario de Bio-Org&#x000e1;nica Antonio Gonz&#x000e1;lez (IUBO AG), Centro de Investigaciones Biom&#x000e9;dicas de Canarias (CIBICAN), Universidad de La Laguna (ULL), Avda. Astrof&#x000ed;sico F. S&#x000e1;nchez 2, 38206 La Laguna, Tenerife, Spain; <email>lecartuche@utpl.edu.ec</email> (L.C.); <email>jjfercas@ull.edu.es</email> (J.J.F.)</aff><aff id="af2-marinedrugs-17-00588"><label>2</label>Departamento de Qu&#x000ed;mica y Ciencias Exactas, Secci&#x000f3;n Qu&#x000ed;mica B&#x000e1;sica y Aplicada, Universidad T&#x000e9;cnica Particular de Loja (UTPL), San Cayetano alto s/n, A.P. 1101608 Loja, Ecuador</aff><aff id="af3-marinedrugs-17-00588"><label>3</label>Instituto Universitario de Enfermedades Tropicales y Salud P&#x000fa;blica de Islas Canarias, Departamento de Obstetricia y Ginecolog&#x000ed;a, Pediatr&#x000ed;a, Medicina Preventiva y Salud P&#x000fa;blica, Toxicolog&#x000ed;a, Medicina Legal y Forense y Parasitolog&#x000ed;a, Universidad de La Laguna, Avda. Astrof&#x000ed;sico F. S&#x000e1;nchez s/n, 38206 La Laguna, Tenerife, Spain; <email>mreyesba@ull.edu.es</email> (M.R.-B.); <email>isifaoui@ull.edu.es</email> (I.S.); <email>alu0101283227@ull.edu.es</email> (I.A.-J.); <email>jpinero@ull.edu.es</email> (J.E.P.)</aff><aff id="af4-marinedrugs-17-00588"><label>4</label>Departamento de Qu&#x000ed;mica Org&#x000e1;nica, Universidad de La Laguna (ULL), Avda. Astrof&#x000ed;sico F. S&#x000e1;nchez, 2, 38206 La Laguna, Tenerife, Spain</aff><author-notes><corresp id="c1-marinedrugs-17-00588"><label>*</label>Correspondence: <email>jmlorenz@ull.edu.es</email> (J.L.-M.); <email>adiazmar@ull.edu.es</email> (A.R.D.-M.); Tel.: +34-922-6502 (ext. +6111) (J.L.-M.); +34-922-6502 (ext. +6380) (A.R.D.-M.)</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>17</volume><issue>10</issue><elocation-id>588</elocation-id><history><date date-type="received"><day>30</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Indolocarbazoles are a family of natural alkaloids characterized by their potent protein kinase and topoisomerase I inhibitory activity. Among them, staurosporine (<bold>1</bold>) has exhibited promising inhibitory activity against parasites. Based on new insights on the activity and mechanism of action of STS in <italic>Acanthamoeba</italic> parasites, this work reports the isolation, identification, and the anti-<italic>Acanthamoeba</italic> activity of the minor metabolites 7-oxostaurosporine (<bold>2</bold>), 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>), and streptocarbazole B (<bold>4</bold>), isolated from cultures of the mangrove strain <italic>Streptomyces sanyensis.</italic> A clear correlation between the antiparasitic activities and the structural elements and conformations of the indolocarbazoles <bold>1</bold>&#x02013;<bold>4</bold> was observed. Also, the study reveals that 7-oxostaurosporine (<bold>2</bold>) affects membrane permeability and causes mitochondrial damages on trophozoites of <italic>A. castellanii</italic> Neff.</p></abstract><kwd-group><kwd>indolocarbazole</kwd><kwd>staurosporine</kwd><kwd><italic>Streptomyces sanyensis</italic></kwd><kwd>antiparasitic activities</kwd><kwd><italic>Acanthamoeba</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-marinedrugs-17-00588"><title>1. Introduction</title><p>Indolocarbazoles (ICZs) are a large family of alkaloid natural compounds characterized by their protein kinase, particularly tyrosine kinase, inhibitory activity. These enzymes are responsible for regulating essential aspects of cell metabolism including cell cycle progression; consequently, ICZs exert potent cytotoxic effect on cancer cells [<xref rid="B1-marinedrugs-17-00588" ref-type="bibr">1</xref>,<xref rid="B2-marinedrugs-17-00588" ref-type="bibr">2</xref>,<xref rid="B3-marinedrugs-17-00588" ref-type="bibr">3</xref>]. </p><p>ICZs have been isolated from several sources including bacteria, slime molds, cyanobacteria, and marine invertebrates [<xref rid="B1-marinedrugs-17-00588" ref-type="bibr">1</xref>]. The first isolated compound, staurosporine (STS), was obtained from a culture of a soil actinomycete (<italic>Streptomyces staurosporeus</italic>) in 1977 [<xref rid="B4-marinedrugs-17-00588" ref-type="bibr">4</xref>] at the Kitasato Institute (Mizusawa City, Japan) and nine years later, its mechanism of action was discovered through non-selective protein kinase inhibition [<xref rid="B5-marinedrugs-17-00588" ref-type="bibr">5</xref>,<xref rid="B6-marinedrugs-17-00588" ref-type="bibr">6</xref>]. Related compounds demonstrated the same effect, thus opening the route for the discovery of a new class of antincancer drugs [<xref rid="B7-marinedrugs-17-00588" ref-type="bibr">7</xref>,<xref rid="B8-marinedrugs-17-00588" ref-type="bibr">8</xref>]. In addition, two synthetic derivatives of the ICZ antibiotic, K252a, were proven to be potent inducers of DNA cleavage complex by interacting with topoisomerase I, increasing the interest of pharmaceutical industries in this family of compounds [<xref rid="B9-marinedrugs-17-00588" ref-type="bibr">9</xref>].</p><p>STS has exhibited promising inhibitory activity against parasites [<xref rid="B10-marinedrugs-17-00588" ref-type="bibr">10</xref>,<xref rid="B11-marinedrugs-17-00588" ref-type="bibr">11</xref>,<xref rid="B12-marinedrugs-17-00588" ref-type="bibr">12</xref>]; since protein kinases (PKs) play critical roles in the growth and mechanism of infection of some parasites such as <italic>Trypanosoma</italic> and <italic>Leishmania</italic> spp., and parasitic PKs differ from their mammal counterparts, these antibiotics result attractive for the development of specific inhibitors [<xref rid="B13-marinedrugs-17-00588" ref-type="bibr">13</xref>]. Additionally, it has been demonstrated that STS induced cell death in blood forms of <italic>Trypanosoma brucei</italic> in a dose-dependent manner, stimulating the activation of apoptosis by releasing EndoG from mitochondrial disruption under ROS production [<xref rid="B14-marinedrugs-17-00588" ref-type="bibr">14</xref>]; however, to the best of our knowledge there is no information about the antiparasitic effect of streptocarbazole B, 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine, and 7-oxostaurosporine which are the focus of this research. </p><p>Derivative 7-oxostaurosporine (7OSTS) was first isolated from <italic>Streptomyces platensis</italic> [<xref rid="B15-marinedrugs-17-00588" ref-type="bibr">15</xref>]. 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (4&#x02032;D4&#x02032;OSTS) from <italic>S. longisporoflavus</italic> [<xref rid="B16-marinedrugs-17-00588" ref-type="bibr">16</xref>] and more recently, streptocarbazoles A (SCZ A) and B (SCZ B) from <italic>Streptomyces</italic> sp. FMA strain [<xref rid="B17-marinedrugs-17-00588" ref-type="bibr">17</xref>], all of them exerting strong protein kinase inhibitory effects and consequently, acting as anticancer agents. </p><p>Infections caused by <italic>Acanthamoeba</italic> spp. affect millions of people worldwide as well as the deficiency of satisfactory treatments. The lack of effectiveness due to drug resistance and high toxicity are the main drawbacks of currently used chemotherapeutics, which evidence that the search for new chemical entities to fight parasitic infections remains a critical need. Recently, we have reported a detailed study on the activity and mechanism of action of STS in <italic>Acanthamoeba</italic> and the programmed cell death via mitochondrial pathway [<xref rid="B18-marinedrugs-17-00588" ref-type="bibr">18</xref>]. The aim of this research is based on the isolation and identification of the minor metabolites 7OSTS (<bold>2</bold>), 4&#x02032;D4&#x02032;OSTS (<bold>3</bold>), and SCZB (<bold>4</bold>) (<xref ref-type="fig" rid="marinedrugs-17-00588-f001">Figure 1</xref>) from a mangrove-derived bacterium <italic>S. sanyensis</italic> PBLC04 strain collected in the coast of Ecuador, and to value their anti-<italic>Acanthamoeba</italic> activity. Mangroves are singular ecosystems, characterized for their high biodiversity and, hence, ideal for the discovery of new drugs from microbial sources. </p></sec><sec sec-type="results" id="sec2-marinedrugs-17-00588"><title>2. Results and Discussion</title><sec id="sec2dot1-marinedrugs-17-00588"><title>2.1. Strain Isolation, Culture, and Identification of Indolocarbazol Metabolites </title><p><italic>Streptomyces sanyensis</italic> PBLC04 strain was isolated from sediment samples collected in Jambel&#x000ed; mangrove at the southwest coast of Ecuador. 30 L of the strain were cultured using Fernbach bottles and seawater-based modified A1 medium. Cultures of <italic>S. sanyensis</italic> were centrifuged, and the biomass pellet was extracted using a mixture of MeOH:EtOAc:Acetone (2:7:3). Resulting extracts were combined, filtered, and dried in vacuo at 30 &#x000b0;C in a rotary evaporator.</p><p>The salt-free biomass extract was chromatographed by filtration on Sephadex-LH-20 with methanol as eluent. The bioassay-guided analysis of the fractions led us to the active fraction SF3 and SF4 against <italic>Acanthamoeba castellanii</italic> Neff with IC<sub>50</sub> values of 10.68 &#x000b1; 0.41 &#x000b5;g/mL and 0.44 &#x000b1; 0.03 &#x000b5;g/mL, respectively. These fractions ware further chromatographed on a RP18 prepacked cartridge applying a gradient elution system of H<sub>2</sub>O:MeOH, buffered with 5 mM NH<sub>4</sub>OAc. The active fractions exhibited characteristic signals for ICZs in the <sup>1</sup>H-NMR spectrum. Final purification on a silica-gel open column using CHCl<sub>3</sub>:MeOH (9:1) yielded pure staurosporine (<bold>1</bold>) (STS), the major compound, which represents 0.52% of the total content of the biomass extract, whereas pure minor compounds 7-oxostaurosporine (<bold>2</bold>) (7OSTS), 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>) (4&#x02032;D4&#x02032;OSTS), and streptocarbazole B (<bold>4</bold>) (SCZ B) required elution with <italic>n</italic>-Hex:EtOAc:MeOH (2:7:1). The NMR spectra, mass spectrometry, and optical rotation data for compounds <bold>1</bold>&#x02013;<bold>4</bold> were compared with those previously reported in the chemical literature to confirm their structures [<xref rid="B4-marinedrugs-17-00588" ref-type="bibr">4</xref>,<xref rid="B15-marinedrugs-17-00588" ref-type="bibr">15</xref>,<xref rid="B16-marinedrugs-17-00588" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-17-00588" ref-type="bibr">17</xref>]. Spectral data and detailed tables with the chemical shifts and HMBC and ROESY correlations are included in the <xref ref-type="app" rid="app1-marinedrugs-17-00588">Supplementary Materials</xref>.</p></sec><sec id="sec2dot2-marinedrugs-17-00588"><title>2.2. Anti-Acanthamoeba Activity on Parasite Trophozoites</title><p>The antiamoebic activities of natural indolocarbazole metabolites identified in <italic>Streptomyces sanyensis</italic>, compounds <bold>1</bold>&#x02013;<bold>4</bold>, were tested against trophozoites of the strains: <italic>A. castellanii</italic> Neff, <italic>A. griffini</italic> and <italic>A. polyphaga</italic>. The inhibitory concentrations (IC<sub>50</sub>) were calculated in &#x000b5;M concentrations and are shown in <xref rid="marinedrugs-17-00588-t001" ref-type="table">Table 1</xref>, and compared with those of chlorhexidine and voriconazole, reference drugs for the treatment of amoebic keratitis (AK), an infection caused by <italic>Acanthamoeba</italic> sp. [<xref rid="B19-marinedrugs-17-00588" ref-type="bibr">19</xref>]. Compound 7OSTS (<bold>2</bold>) showed to be as effective as its congener STS (<bold>1</bold>) and the reference compound voriconazole against all tested <italic>Acanthamoeba</italic> spp. Compounds <bold>3</bold> and <bold>4</bold> showed a similar activity and selectivity against the three tested strains, being more active for <italic>A. castellanii</italic> Neff.</p><p>Additionally, three commercially available indolocarbazole compounds rebeccamycin (<bold>5</bold>), K252c (<bold>6</bold>), and arcyriaflavin A (<bold>7</bold>) were tested. Compounds <bold>5</bold>&#x02013;<bold>7</bold> showed to be less active than <bold>1</bold> and <bold>2</bold>, while K252c (<bold>6</bold>) seems to be selective against <italic>A. griffini.</italic></p></sec><sec id="sec2dot3-marinedrugs-17-00588"><title>2.3. Cytotoxicity Assays in Murine Macrophages</title><p>On the other hand, the potential effectiveness of compounds as antiparasitics depends on their toxicity. As well established in our laboratory [<xref rid="B20-marinedrugs-17-00588" ref-type="bibr">20</xref>,<xref rid="B21-marinedrugs-17-00588" ref-type="bibr">21</xref>], the toxicity of all compounds was evaluated at the concentration that inhibits 50% of murine macrophages (<xref rid="marinedrugs-17-00588-t002" ref-type="table">Table 2</xref>). </p><p>Compound <bold>2</bold>, 7OSTS, turned out to be the most cytotoxic with a CC&#x02085;&#x02080; of 5.20 &#x000b1; 1.75 &#x000b5;M. Nevertheless, this CC<sub>50</sub> value was significantly higher than the IC<sub>50</sub> values obtained against the strains <italic>A. castellanii</italic> and <italic>A.</italic> graffini. 4&#x02032;D4&#x02032;OSTS (<bold>3</bold>) and ICZ B (<bold>4</bold>) were the least toxic among all tested compounds against murine macrophage J774A.1.</p></sec><sec id="sec2dot4-marinedrugs-17-00588"><title>2.4. In Vitro Activity against Acanthamoeba castellanii Neff Cysts</title><p>When 7OSTS (<bold>2</bold>) was incubated with mature cysts of <italic>A. castellanii</italic> Neff, non-viable cysts were observed after incubation up to 144 h. In <xref ref-type="fig" rid="marinedrugs-17-00588-f002">Figure 2</xref>, the activity of 7OSTS (<bold>2</bold>) against <italic>A. castellanii</italic> Neff cysts is observed, with an IC<sub>50</sub> of 0.92 &#x000b1; 0.33 &#x000b5;M. Non-viable cysts were observed when compared to a negative control of trophozoites and not treated mature cysts. </p></sec><sec id="sec2dot5-marinedrugs-17-00588"><title>2.5. Evaluation of the Mechanism of Action of 7OSTS</title><p>Among minor compounds, 7OSTS (<bold>2</bold>) was the selected molecule to continue the studies on the mode of action on <italic>A. castellanii</italic> Neff based on the activity values. The search for new therapies which do not produce necrotic cell death is necessary in order to avoid an excessive inflammatory response. Therefore, events involved during programmed cell death or apoptosis-like processes are subject of study and include several morphological stages such as nuclear DNA fragmentation, chromatin condensation or damages at mitochondrial level, among others [<xref rid="B22-marinedrugs-17-00588" ref-type="bibr">22</xref>]. Consequently, our next objective was to recognize the mechanism of action of 7OSTS (<bold>2</bold>), through the evaluation of changes in the mitochondrial membrane potential, ATP cell levels, chromatin condensation, and plasmatic membrane integrity. </p><p>A double-stain assay was performed to determine the effect on chromatin condensation. 7OSTS-treated cells at the IC<sub>90</sub> concentration (2.91 &#x000b1; 0.67 &#x000b5;M) stained positive in the assay as shown by the bright-blue nuclei stain in <xref ref-type="fig" rid="marinedrugs-17-00588-f003">Figure 3</xref>A, which indicates 7OSTS induces chromatin condensation. Moreover, it is important to highlight that the morphology of the trophozoites treated with IC<sub>90</sub> of 7OSTS (<bold>2</bold>) (<xref ref-type="fig" rid="marinedrugs-17-00588-f003">Figure 3</xref>A) show rounded and smaller shape compared to the negative control (<xref ref-type="fig" rid="marinedrugs-17-00588-f003">Figure 3</xref>B). which are common events when a cell is under a programmed cell death pathway [<xref rid="B22-marinedrugs-17-00588" ref-type="bibr">22</xref>].</p><p>7OSTS (<bold>2</bold>) also showed an induction of mitochondrial malfunction. <xref ref-type="fig" rid="marinedrugs-17-00588-f004">Figure 4</xref> shows that <italic>A. castellanii</italic> Neff cells treated with 7OSTS (IC<sub>90</sub>) exhibit higher green fluorescence (<bold>A</bold>) when compared with the negative control (<bold>B</bold>). The green fluorescence indicates the presence of JC-1 (5,5&#x02032;,6,6&#x02032;-Tetrachloro-1,1&#x02032;,3,3&#x02032;-tetraethyl-imidacarbocyanine iodide) monomers, which reveals a decrease of the mitochondrial membrane potential. In the negative control, the mitochondrial membrane potential is unaltered, showing a red fluorescence caused by JC-1 dimers. </p><p>On the other hand, after incubation of <italic>A. castellanii</italic> Neff with the IC<sub>90</sub> of 7OSTS (<bold>2</bold>) for 24 h, the ATP level was reduced to 45% compared to the negative control (<xref ref-type="fig" rid="marinedrugs-17-00588-f005">Figure 5</xref>). This result reveals that the cells maintained one half of the ATP level after treatment with 7OSTS, and confirms the mitochondrial damage.</p><p>7OSTS (<bold>2</bold>) caused plasma membrane permeability in treated cells. Membrane permeabilization experiment on <italic>A. castellanii</italic> Neff cells treated with the IC<sub>90</sub> of 7OSTS (<bold>2</bold>), showed plasmatic membrane damage after 24 h of treatment. Nevertheless, it is also important to reference that even though the membrane was damaged, cell integrity was maintained as confirmed in <xref ref-type="fig" rid="marinedrugs-17-00588-f006">Figure 6</xref>. </p><p>ICZ derivatives have been the focus of numerous research groups, mainly in the area of chemotherapeutics against cancer, Alzheimer&#x02019;s disease, and other neurodegenerative disorders [<xref rid="B1-marinedrugs-17-00588" ref-type="bibr">1</xref>,<xref rid="B2-marinedrugs-17-00588" ref-type="bibr">2</xref>,<xref rid="B3-marinedrugs-17-00588" ref-type="bibr">3</xref>]. Thus, several STS analogues have advanced in clinical trials, broadly subdivided into two groups based on their target profile. The first group is represented by STS and includes compounds that are potent inhibitors of protein kinases. On the other hand, the second group are STS analogues modified in the sugar moiety and therefore do not inhibit protein kinases, but instead are used as potent stabilizers of DNA topoisomerase I. Among the natural and biosynthetically produced STS analogues, the 7-hydroxy-derivatives has been tested for clinical phase for several forms of cancer such as pancreas, breast, and lymphoma [<xref rid="B23-marinedrugs-17-00588" ref-type="bibr">23</xref>].</p><p>The initial studies on the STS-PK complex were directed towards the kinase models PKA and CDK2. These studies and those completed later have indicated the crucial hydrogen bond interactions between the heteroatoms of the lactam moiety of the alkaloids with a conserved glutamic acid residue (Glu). On the other side, the methyl amino group at C-4&#x02032; of the sugar moiety is involved in the formation of two hydrogen bonds with amino acid residues such as Glu and aspartic acid (Asp), part of the protein catalytic site. These interactions force a boat conformation of the sugar ring of the ligand and a perpendicular orientation to the planar aromatic indolocarbazole nucleus when the ICZ-family of compounds inhibit protein kinases. Another important point is that the binding affinity of ICZs increases with the presence of hydrogen bonds between the nitrogen of the methyl amino moiety at C-4&#x02032; with neighboring protein residues [<xref rid="B6-marinedrugs-17-00588" ref-type="bibr">6</xref>,<xref rid="B24-marinedrugs-17-00588" ref-type="bibr">24</xref>].</p><p>Commercial ICZ compounds obtained from their natural sources are available for biochemical studies (<xref ref-type="fig" rid="marinedrugs-17-00588-f007">Figure 7</xref>). Rebeccamycin (<bold>5</bold>) is an indolocarbazole antibiotic produced, among other actinomycetes, by <italic>Saccharothrix aerocolonigenes</italic> [<xref rid="B25-marinedrugs-17-00588" ref-type="bibr">25</xref>]. It is a DNA-binding molecule that inhibits topoisomerase I activity [<xref rid="B26-marinedrugs-17-00588" ref-type="bibr">26</xref>,<xref rid="B27-marinedrugs-17-00588" ref-type="bibr">27</xref>,<xref rid="B28-marinedrugs-17-00588" ref-type="bibr">28</xref>,<xref rid="B29-marinedrugs-17-00588" ref-type="bibr">29</xref>]. Rebeccamycin shows cytotoxic activity against human lung, colon, and nasopharyngeal carcinoma cell lines with IC<sub>50</sub> values that range from 0.4&#x02013;98 &#x000b5;M [<xref rid="B30-marinedrugs-17-00588" ref-type="bibr">30</xref>]. The STS aglycon is known as K252c (<bold>6</bold>). It is an efficient protein kinase C (PKC) inhibitor (IC<sub>50</sub> 2.45 &#x000b5;M) compared to its inhibitory protein kinase A (PKA) activity (IC<sub>50</sub> 25.7 &#x000b5;M) [<xref rid="B26-marinedrugs-17-00588" ref-type="bibr">26</xref>]. Arcyriaflavin A (<bold>7</bold>), the 7OSTS aglycon, is an inhibitor of cyclin-dependent kinase 4 (CDK4) with an IC<sub>50</sub> = 140 nM, and calcium/calmodulin-dependent protein kinase II (CaMKII; IC<sub>50</sub> = 25 nM), showing selectivity for CDK4 and CaMKII over protein kinase A (PKA; IC<sub>50</sub> &#x0003e; 2 &#x000b5;M) and PKC (IC<sub>50</sub> &#x0003e;100 &#x000b5;M) [<xref rid="B2-marinedrugs-17-00588" ref-type="bibr">2</xref>,<xref rid="B31-marinedrugs-17-00588" ref-type="bibr">31</xref>].</p><p>In this work, we have found a clear correlation between the antiparasitic activities observed and the structural elements and conformations of the indolocarbazole molecules under study (<xref ref-type="fig" rid="marinedrugs-17-00588-f008">Figure 8</xref>). Thus, both STS (<bold>1</bold>) and the 7-oxo derivative (<bold>2</bold>) showed potent activities against the tested species. This fact could be explained based on the conserved interactions reported for many protein kinases, which establish interactions between the lactam group and methyl amine at the C-4&#x02032; position of both compounds. This result agrees with a similar orientation and conformation of <bold>1</bold> and <bold>2</bold>. In addition, in the particular case of <italic>A. polyphaga</italic>, a difference of activity between STS (<bold>1</bold>) and 7OSTS (<bold>2</bold>) was observed, that could be justified based on the positive or negative interaction with the active site of the target PKs, due to the additional functionalization at C-7 position of <bold>2</bold>.</p><p>On the other hand, compounds 4&#x02032;D4&#x02032;OSTS (<bold>3</bold>) and SCZ B (<bold>4</bold>) showed moderate antiamoebic activity compared to <bold>1</bold> and <bold>2</bold>. In the case of <bold>3</bold>, it might be consequence of the absence of the expected hydrogen bond with the methyl amine group at C-4&#x02032; in the PKs inhibition mechanism by ICZs (<xref ref-type="fig" rid="marinedrugs-17-00588-f008">Figure 8</xref>). For compound <bold>4</bold>, a significant structural change in the sugar ring is observed which eliminate all these conserved interactions at C-4&#x02032; position. Furthermore, the different orientation of the sugar moiety could produce strong steric impediments at the active site. Similarly, this structural feature seems to be the cause of the reduced toxicity of <bold>3</bold> and <bold>4</bold> (CC<sub>50</sub> &#x0003e; 40 &#x003bc;M), which confer these compounds a similar selective index to the active 7OSTS (<bold>2</bold>) in treatments against the <italic>A. castellanii</italic> Neff strain. The results obtained with commercial ICZs (<bold>5</bold>&#x02013;<bold>7</bold>) reinforce the relevance of the interactions due to the sugar moiety of STS (<bold>1</bold>) and the 7OSTS (<bold>2</bold>) to improve the antiamoeboid activity.</p></sec></sec><sec id="sec3-marinedrugs-17-00588"><title>3. Materials and Methods</title><sec id="sec3dot1-marinedrugs-17-00588" sec-type="methods"><title>3.1. General Experimental Procedures</title><p>NMR spectra were recorded on a Bruker AVANCE 500 MHz or 600 MHz (Bruker Biospin, Fall&#x000e4;nden, Switzerland), as required. NMR spectra were obtained dissolving samples in CDCl<sub>3</sub> (99.9%) and chemical shifts are reported relative to solvent (&#x003b4;<sub>H</sub> 7.26 and &#x003b4;<sub>C</sub> 77.0 ppm). Bruker AVANCE 600 MHz instrument is equipped with a 5 mm TCI inverse detection cryoprobe (Bruker Biospin, Fall&#x000e4;nden, Switzerland). Standard Bruker NMR pulse sequences were utilized. Optical rotations were measured in CHCl<sub>3</sub> on a PerkinElmer 241 polarimeter (Waltham, MA, USA) by using a Na lamp. HR-ESI-MS data were obtained on a Waters LCT Premier XE Micromass (Manchester, UK) and VG-AutoSpec Micromass spectrometers (Manchester, UK), respectively. IR spectra were recorded on a Bruker IFS66/S (Ettlingen, Germany) equipped with an ATR accessory using CHCl<sub>3</sub> solutions. EnSpire <sup>&#x000ae;</sup> Multimode Reader (Perkin Elmer, Waltham, MA, USA) using absorbance values of alamarBlue<sup>&#x000ae;</sup> reagent (Bio-Rad Laboratories, Oxford, UK). HPLC (high performance liquid chromatography) separations were carried out with an Agilent 1260 Infinity Quaternary LC equipped with a Diode Array Detector (Waldbronn, Germany). TLC (Thin layer chromatography) (Merck, Darmstadt, Germany) was visualized by UV light (254 nm) and spraying with cobalt chloride reagent (2% in sulfuric acid, 10%) and heating.</p></sec><sec id="sec3dot2-marinedrugs-17-00588"><title>3.2. Biological Material</title><p><italic>Streptomyces sanyensis</italic> PBLC04 strain was collected in Jambel&#x000ed; mangrove (3&#x000b0;15&#x02032;792&#x02033; S, 80&#x000b0;00&#x02032;739&#x02033; W&#x02013;03&#x000b0;17&#x02032;711&#x02033; S, 80&#x000b0;01&#x02032;924&#x02033; W), Ecuador. The strain is included in the microbial collection of Universidad T&#x000e9;cnica Particular de Loja (UTPL, Loja-Ecuador). Samples of marine sediment were collected in 15 mL Falcon tubes from 1 to 3 m depth and put into sterile polythene bags. Stamps of pulverized samples were seeded on agar plates of a sea water-based medium (10 g starch, 4 g yeast extract, 2 g peptone, 1 g CaCO <sub>3</sub>, 40 mg Fe<sub>2</sub>(SO <sub>4</sub>)<sub>3</sub> 4H<sub>2</sub>O, 100 mg KB, 15 g Bacto Agar, per liter), acidic gauze medium, humic acid medium, and TCG medium, all of them containing 1% of polymyxin B and cycloheximide as inhibitors of undesired growth. The plates were incubated at 30 &#x000b0;C and observed periodically. Gram staining was used to identify branched filamentous Gram-positive bacteria.</p></sec><sec id="sec3dot3-marinedrugs-17-00588"><title>3.3. Cultures and Preparation of Crude Extracts</title><p><italic>Streptomyces sanyensis</italic> PBLC04 strain was cultured in Fernbach bottles using a modified seawater-based medium (A1) that consisting of 75% seawater containing 10 g starch, 4 g yeast extract, 2 g proteose peptone, 1 g calcium carbonate, supplemented with 5 mL/L of a solution of potassium bromide (67 mM) and ferric sulfate (20 mM). Fernbach flasks with 1 L each were maintained in an orbital shaker at 30 &#x000b0;C and 200 rpm for 7 days. Cultures of <italic>S. sanyensis</italic> PBLC04 were then centrifuged at 5000 rpm for 10 min at 4 &#x000b0;C to collect the cell biomass. Supernatant was treated by Amberlite<sup>&#x000ae;</sup> XAD7-HP resin (20 g/L) addition and stirred for 3 h for the recuperation of excreted substances. After filtration, both the resin and the biomass pellet were separately extracted using a mixture of MeOH:EtOAc:Acetone (2:7:3) for 12 h at 120 rpm in an orbital shaker. Resulting extracts were filtered, dried in vacuo at 30 &#x000b0;C in a rotary evaporator and stored a &#x02212;80 &#x000b0;C until used.</p></sec><sec id="sec3dot4-marinedrugs-17-00588"><title>3.4. Isolation of Indolocarbazole Metabolites</title><p>The obtained crude extract 12.6 g was fractionated by gel filtration on Sephadex LH-20 column, eluting with methanol to yield 10 fractions that were finally gathered in four final fractions according to TLC and <sup>1</sup>H-NMR analysis. Thin layer chromatography (TLC) monitoring was used with cobalt chloride (2%) as spraying reagent. The bioassay-guided analysis of the Sephadex LH-20 fractions led us to an active fraction SF3 and SF4 against <italic>Acanthamoeba castellanii</italic> Neff with IC<sub>50</sub> values of 10.68 &#x000b1; 0.41 &#x000b5;g/mL and 0.44 &#x000b1; 0.03 &#x000b5;g/mL, respectively; and against <italic>Leishmania amazonensis</italic> with IC<sub>50</sub> values of 0.43 &#x000b1; 0.07 &#x000b5;g/mL and 0.08 &#x000b1; 0.01 &#x000b5;g/mL. These fractions were then chromatographed using a flash chromatography on a RP18 prepacked cartridge (25&#x02013;40 &#x000b5;m, 70 g, G&#x000f6;tec-Labortechnik GmbH) operating in a gradient elution protocol of H<sub>2</sub>O:MeOH, 5mM NH<sub>4</sub>OAc, (20% to 100% MeOH) at 2 mL/min flow. All process was monitored by UV detection at 254 nm. The active fractions those exhibited characteristic signals for ICZs in the <sup>1</sup>H-NMR spectrum and bioactivities against cited parasites were separated by elution on Si-60 open column (230&#x02013;400 mesh, 60 &#x000c5;) using CHCl<sub>3</sub>:MeOH (9:1) yielding 65.9 mg of pure staurosporine (<bold>1</bold>) (STS, 65.6 mg, 0.521%) from SF3; and <italic>n</italic>-Hex:EtOAc:MeOH (2:7:1) to obtained pure the compounds 7-oxostaurosporine (<bold>2</bold>) (1.01 mg, 0.008%), 4&#x02032;-demethylamino-4-oxostaurosporine (<bold>3</bold>), (1.13 mg, 0.009%) and streptocarbazole B (<bold>4</bold>) (SCZ B, 0.91 mg, 0.007%) from SF4.</p><sec id="sec3dot4dot1-marinedrugs-17-00588"><title>3.4.1. Staurosporine, (STS), (1)</title><p>Yellow powder, [&#x003b1;]<inline-formula><mml:math id="mm1"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow/><mml:mi mathvariant="normal">D</mml:mi><mml:mn>20</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> + 43 (<italic>c</italic> 0.3, CHCl<sub>3</sub>); UV (CHCl<sub>3</sub>) &#x003bb;<sub>max</sub> (log &#x003b5;) 297 (4.48) nm. IR &#x003c5;<sub>max</sub> 2920, 2851, 1713, 1568, 1463, and 1318 cm<sup>&#x02212;1</sup>. HRESIMS <italic>m/z</italic> 489.1908 [M + Na]<sup>+</sup>, calc. 489.1897 for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>Na. <sup>1</sup>H and <sup>13</sup>C NMR data see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Table S1</xref>. <sup>1</sup>H and <sup>13</sup>C NMR spectra, see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Supplementary Materials</xref> (<xref ref-type="app" rid="app1-marinedrugs-17-00588">Figures S2 and S3</xref>).</p></sec><sec id="sec3dot4dot2-marinedrugs-17-00588"><title>3.4.2. 7-Oxostaurosporine, (7OSTS), (2)</title><p>Yellow powder, [&#x003b1;]<inline-formula><mml:math id="mm2"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow/><mml:mi mathvariant="normal">D</mml:mi><mml:mn>20</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> +32.0&#x000b0; (<italic>c</italic> 0.1, CHCl<sub>3</sub>); UV (CHCl<sub>3</sub>) &#x003bb;<sub>max</sub> (log &#x003b5;) 243, 265, 288, 305, 319 nm (&#x003b5; 319 nm: 20513.39 L mol<sup>&#x02212;1</sup> cm<sup>&#x02212;1</sup>) nm. IR &#x003c5;<sub>max</sub> 2920, 2851, 1713, 1568, 1463, and 1318 cm<sup>&#x02212;1</sup>. HRESIMS <italic>m/z</italic> 481.1875 [M + H]<sup>+</sup> calcd. 481.1876 for C<sub>28</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub>. <sup>1</sup>H and <sup>13</sup>C NMR data see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Table S2</xref>. <sup>1</sup>H and <sup>13</sup>C NMR spectra, see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Supplementary Materials</xref> (<xref ref-type="app" rid="app1-marinedrugs-17-00588">Figures S5 and S6</xref>).</p></sec><sec id="sec3dot4dot3-marinedrugs-17-00588"><title>3.4.3. 4&#x02019;-Demethylamino-4&#x02032;-oxostaurosporine, (4&#x02032;D4&#x02032;OSTS), (3)</title><p>Yellow powder, [&#x003b1;]<inline-formula><mml:math id="mm3"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow/><mml:mi mathvariant="normal">D</mml:mi><mml:mn>20</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> 22&#x000b0; (<italic>c</italic> 0.12, CHCl<sub>3</sub>); UV (CHCl<sub>3</sub>) &#x003bb;<sub>max</sub> (log &#x003b5;) 248, 268, 293, 319, 335, 352, 368 nm (&#x003b5;<sub>293nm</sub> 23106.25 cm<sup>&#x02212;1</sup>M<sup>&#x02212;1</sup>) nm. IR &#x003c5;<sub>max</sub> 2922, 2853, 2362, 1682., 1456 and 1317 cm<sup>&#x02212;1</sup>. HRESIMS <italic>m/z</italic> 474.1425 [M + Na]<sup>+</sup> calcd. 474.1430 for C<sub>27</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>Na. <sup>1</sup>H and <sup>13</sup>C NMR data, see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Table S3</xref>. <sup>1</sup>H and <sup>13</sup>C NMR spectra, see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Supplementary Materials</xref> (<xref ref-type="app" rid="app1-marinedrugs-17-00588">Figures S8 and S9</xref>).</p></sec><sec id="sec3dot4dot4-marinedrugs-17-00588"><title>3.4.4. Streptocarbazole B, (SCZ B), (4)</title><p>Pale yellow powder, [&#x003b1;]<inline-formula><mml:math id="mm4"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow/><mml:mi mathvariant="normal">D</mml:mi><mml:mn>20</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> &#x02212;27&#x000b0; (<italic>c</italic> 0.09, CHCl<sub>3</sub>); UV (CHCl<sub>3</sub>) &#x003bb;<sub>max</sub> (log &#x003b5;) Its UV spectrum show bands at 245, 268, 291, 318, 334, 348, 366 nm (&#x003b5; 291nm: 22458.82 cm<sup>&#x02212;1</sup>M<sup>&#x02212;1</sup>) nm. IR &#x003c5;<sub>max</sub> 2928, 1682, and 1456 cm<sup>&#x02212;1</sup>. HRESIMS <italic>m/z</italic> 488.1513 [M + Na]<sup>+</sup> calcd. 488.1586 for C<sub>28</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>Na. <sup>1</sup>H and <sup>13</sup>C NMR data see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Table S4</xref>. <sup>1</sup>H and <sup>13</sup>C NMR spectra, see <xref ref-type="app" rid="app1-marinedrugs-17-00588">Supplementary Materials</xref> (<xref ref-type="app" rid="app1-marinedrugs-17-00588">Figures S11 and S12</xref>).</p></sec></sec><sec id="sec3dot5-marinedrugs-17-00588"><title>3.5. Commercial ICZ Analogs <italic><bold>5</bold>&#x02013;<bold>7</bold></italic></title><p>Indolocarbazole derivatives rebeccamycin (<bold>5</bold>) (CAS no. 93908-02-2), K252c (<bold>6</bold>) (CAS no. 85753-43-1), and arcyriaflavin A (<bold>7</bold>) (CAS no. 118458-54-1), were all acquired from Cayman Chemical (Ann Arbor, MI, USA).</p></sec><sec id="sec3dot6-marinedrugs-17-00588"><title>3.6. Cell Culture</title><p>The amoeba strain used in this study was the type strain: <italic>Acanthamoeba castellanii</italic> Neff (ATCC 30010) which was axenically grown in PYG medium (0.75% (<italic>w</italic>/<italic>v</italic>) proteose peptone, 0.75% (<italic>w</italic>/<italic>v</italic>) yeast extract and 1.5% (<italic>w</italic>/<italic>v</italic>) glucose) containing 40 &#x000b5;g/mL of gentamicin (Biochrom AG, Cultek, Granollers, Barcelona, Spain). The murine macrophages J774A.1 (ATCC TIB-67) cell line was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37 &#x000b0;C and 5% CO<sub>2</sub> atmosphere, was used for the cytotoxicity assays. Successively, the evaluated molecules were also tested against two clinical isolates, <italic>Acanthamoeba</italic>
<italic>griffini</italic>, genotype T3 obtained in a previous study [<xref rid="B32-marinedrugs-17-00588" ref-type="bibr">32</xref>], and <italic>Acanthamoeba polyphaga</italic> genotype T4 ATCC 30461, both axenically grown in the same medium as <italic>A</italic>. <italic>castellanii</italic> Neff.</p></sec><sec id="sec3dot7-marinedrugs-17-00588"><title>3.7. In Vitro Activity Against Acanthamoeba spp. Trophozoites</title><p>To evaluate the biological activity of the fractions and molecules, the anti-<italic>Acanthamoeba</italic> experiments were carried out using the alamarBlue<sup>&#x000ae;</sup> colorimetric assay, as it was previously described [<xref rid="B22-marinedrugs-17-00588" ref-type="bibr">22</xref>]. Briefly, <italic>Acanthamoeba</italic> strain was seeded in triplicate on 96-well microtiter plates (ThermoFisher&#x02122;, Waltham, MA, USA) with 50 &#x000b5;L from a stock solution of 5 &#x000d7; 10<sup>4</sup> cells/mL and 50 &#x000b5;L of serial dilutions of the evaluated molecules in each well (1% DMSO was used to dissolve the highest dose of the compounds with no effects on the parasites). Two reference treatments [<xref rid="B33-marinedrugs-17-00588" ref-type="bibr">33</xref>] such as chlorhexidine (chlorhexidine digluconate; Alfa Aesar) and voriconazole (Sigma), were used as positive controls. Finally, the alamarBlue<sup>&#x000ae;</sup> Reagent (Life Technologies, Madrid, Spain) was placed into each well at an amount equal to 10% of the final volume. Plates were incubated for 96 h at 26 &#x000b0;C with a slight agitation until their measurement in the EnSpire<sup>&#x000ae;</sup> Multimode Plate Reader (Perkin Elmer, Madrid, Spain) using fluorescence, at 570/585 nm.</p></sec><sec id="sec3dot8-marinedrugs-17-00588"><title>3.8. In Vitro Activity against Acanthamoeba Castellanii Neff Cysts</title><p>On the other side, cysticidal activity of 7OSTS (<bold>2</bold>) was determined also using the alamarBlue&#x02122; reagent and confirmed visually by inverted microscopy. Cysts of <italic>A. castellaniii</italic> Neff were prepared as previously described [<xref rid="B34-marinedrugs-17-00588" ref-type="bibr">34</xref>,<xref rid="B35-marinedrugs-17-00588" ref-type="bibr">35</xref>]. First of all, trophozoites were transferred from PYG medium based cultures (trophozoite medium) to Neff&#x02019;s encystment medium (NEM; 0.1 M KCl, 8 mM MgSO4&#x000b7;7H<sub>2</sub>O, 0.4 mM CaCl2&#x000b7;2H<sub>2</sub>O, 1 mM NaHCO<sub>3</sub>, 20 mM ammediol [2-amino-2-methyl-1,3-propanediol; Sigma Aldrich Chemistry Ltd., Madrid, Spain], pH 8.8, at 25 &#x000b0;C) and were cultured in this medium with gently shaking for a week in order to obtain mature cysts. In order to carry out the cysticidal assay, mature cysts were harvested and washed twice with PYG medium. Serial dilutions of 7OSTS (<bold>2</bold>) were made in PYG and place onto sterile 96-well microtiter plates. 5&#x000b7;10<sup>4</sup> mature cysts of <italic>Acanthamoeba</italic>/mL were added to the wells with 50 &#x000b5;L of 7OSTS (<bold>2</bold>) dilutions. After 7 days of incubation, the plate was centrifuged at 3000 rpm for 10 min. The supernatant was removed and replaced with 100 &#x000b5;L of fresh PYG medium in each well. Finally, 10 &#x003bc;L of the alamarBlue<sup>&#x000ae;</sup> Reagent was placed into each well. The plates were then incubated for 144 h at 28 &#x000b0;C and the emitted fluorescence was measured with the EnSpire<sup>&#x000ae;</sup> Multimode Plate Reader (Perkin Elmer, Madrid, Spain) using fluorescence, at 570/585 nm.</p></sec><sec id="sec3dot9-marinedrugs-17-00588"><title>3.9. Cytotoxicity Test</title><p>The cytotoxicity effect of active molecules was evaluated in murine macrophage J774A.1 cell line (ATCC # TIB-67) following the same protocol described above for <italic>Acanthamoeba</italic> trophozoites. Then, plates containing alamarBlue<sup>&#x000ae;</sup> were incubated for 24 h at 37 &#x000b0;C in presence of CO<sub>2</sub> at 5%.</p></sec><sec id="sec3dot10-marinedrugs-17-00588"><title>3.10. Statistical Analysis</title><p>The percentage of the growth inhibition, 50% inhibitory concentration (IC<sub>50</sub> or CC<sub>50</sub>), was calculated by nonlinear regression analysis with 95% confidence limits using Sigma Plot 12.0 statistical analysis software (Systat Software). All experiments were performed three times, and the mean values were also calculated. A paired two-tailed <italic>t</italic>-test was used for analysis of the data. Values of <italic>p</italic> &#x0003c; 0.05 were considered significant.</p></sec><sec id="sec3dot11-marinedrugs-17-00588"><title>3.11. Double-Stain Assay for Programmed Cell Death Determination</title><p>10<sup>5</sup> amoebas/well were incubated in a 24-well plate with the previously calculated IC<sub>90</sub> of 7OSTS for 24 h. A double-stain apoptosis detection kit (Hoechst 33342/PI) (ThermoFisher&#x02122;, Waltham, MA, USA) was used to carry out the experiment following the manufacturer&#x02019;s recommendations. The images were obtained using the EVOS FL Cell Imaging System AMF4300, Life Technologies, USA. The double-staining pattern allows the identification of live cells with low level of fluorescence, cells undergoing PCD with a higher level of blue fluorescence (as chromatin condenses), and dead cells which will show low-blue and high-red fluorescence (as the propidium iodide stain enters the nucleus of dead cells).</p></sec><sec id="sec3dot12-marinedrugs-17-00588"><title>3.12. Analysis of Mitochondrial Membrane Potential</title><p>The use of JC-1 mitochondrial membrane potential detection kit (Cayman Chemical) it is possible to detect the collapse of an electrochemical gradient across the mitochondrial membrane during apoptosis process. 10<sup>5</sup> amoebas/mL were treated with IC<sub>90</sub> of 7OSTS (<bold>2</bold>) for 24 h, the cells were centrifuged (1000 rpm &#x000d7; 10 min) and suspended in JC-1 buffer. Images were taken on the EVOS FL inverted microscope. The staining pattern allows the identification of two groups in a cellular population: live cells will show only red fluorescence, but cells with low mitochondrial potential (undergoing PCD) will show a higher level of green fluorescence.</p></sec><sec id="sec3dot13-marinedrugs-17-00588"><title>3.13. Measurement of ATP Levels</title><p>An appropriate level of ATP is necessary to maintain the cell metabolism. The effect of the drug on the ATP production was evaluated by incubating (10<sup>5</sup>) of cells/mL with the previously calculated IC<sub>90</sub> of 7OSTS (<bold>2</bold>) using the CellTiter-Glo Luminescent Cell Viability Assay. The luminescence of each assay was measured on the EnSpire<sup>&#x000ae;</sup>.</p></sec><sec id="sec3dot14-marinedrugs-17-00588"><title>3.14. Plasma Membrane Permeability </title><p>In order to detect alterations of the membrane permeability in treated cells, the SYTOX Green (ThermoFischer<sup>TM</sup>) assay was performed. Briefly, 10<sup>5</sup> trophozoite were washed and incubated in saline solution with SYTOX Green at a final concentration of 1 &#x003bc;M for 15 min in darkness. After that, IC<sub>90</sub> of 7OSTS (<bold>2</bold>) was added to the cells and incubated for 24 h. Cells were observed and pictures were taken on the EVOS FL inverted microscope.</p></sec></sec><sec sec-type="conclusions" id="sec4-marinedrugs-17-00588"><title>4. Conclusions</title><p>It is known that infections caused by <italic>Acanthamoeba</italic> spp. affect millions of people worldwide as well as the deficiency of satisfactory treatments. The lack of effectiveness due to drug resistance, and high toxicity are the main drawbacks of currently used drugs. Current therapeutic options against AK rely on the application of biguanides (mainly chlorhexidine or polyhexamethylene biguanide (PHMB)) and azoles (voriconazole) both as eye drops and/or topical. These agents are able to eliminate the trophozoite stage, however the concentrations needed to kill the cysts are usually higher and thus toxic to the eye of the patients. Moreover, these options are lengthy and require application even each hour complicating patients&#x02019; healing [<xref rid="B28-marinedrugs-17-00588" ref-type="bibr">28</xref>]. Therefore, there is an urgent need to develop new agents to treat AK.</p><p>Based on the knowledge of indolocarbazole-type metabolites and their interactions with protein kinases, in this work we have been able to hypothesize about their response against <italic>Acanthamoeba</italic> parasites. Thus, assuming STS (<bold>1</bold>) as a leader compound, it is possible to conclude that in <italic>Acanthamoeba</italic> spp., both <bold>1</bold> and <bold>2</bold>, seem to present similar interactions with the parasite PKs and, therefore, both compounds show similar ranges of inhibition. Similar structural analysis allowed to predict that, for compounds <bold>3</bold> and <bold>4</bold>, minor activities should be expected. Among minor metabolites, 7OSTS (<bold>2</bold>) was the most active. The study of its mode of action on <italic>A. castellanii</italic> Neff trophozoites showed that 7OSTS (<bold>2</bold>) induced chromatin condensation and triggered important morphological changes of cells, affecting membrane permeability, and causing mitochondrial damage. </p><p>This study reveals the ICZ family as potential molecules or biological tools to explore the mechanism of action and the structure of other families of protein kinases. At the moment, there are not known drugs targeting protein kinases of <italic>Acanthamoeba</italic> spp., fact that increases the value of ICZ compounds. Protein kinases could be an alternative and relevant target to fight against amoeboid infections.</p></sec></body><back><ack><title>Acknowledgments</title><p>IS and ARDM were funded by the Agust&#x000ed;n de Betancourt Programme (Cabildo de Tenerife-ULL). Authors acknowledge the use of General Research Support Services of University of La Laguna (SEGAI-ULL). </p></ack><app-group><app id="app1-marinedrugs-17-00588"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/1660-3397/17/10/588/s1">https://www.mdpi.com/1660-3397/17/10/588/s1</uri>, Scheme S1: Isolation and purification of metabolites from <italic>Streptomyces sanyensis</italic>; Figure S1: Chemical structure, atom carbon position numbers and physical data for staurosporine (STS) <bold>1</bold>; Table S1: NMR data for staurosporine (STS) <bold>1</bold> in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K), Figure S2: <sup>1</sup>H NMR spectrum of staurosporine (<bold>1</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S3: <sup>13</sup>C NMR spectrum of staurosporine (<bold>1</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (150 MHz, 298 K); Figure S4: Chemical structure, atom carbon position numbers and physical data for 7-oxostaurosporine (<bold>2</bold>); Table S2: NMR data for 7-oxostaurosporine (<bold>2</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S5: <sup>1</sup>H NMR spectrum of 7-oxostaurosporine (<bold>2</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S6: <sup>13</sup>C NMR spectrum of 7-oxostaurosporine (<bold>2</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (150 MHz, 298 K); Figure S7: Chemical structure, atom carbon position numbers and physical data for 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>); Table S3: NMR data for 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S8: <sup>1</sup>H NMR spectrum of 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S9: <sup>13</sup>C NMR spectrum of 4&#x02032;-demethylamino-4&#x02032;-oxostaurosporine (<bold>3</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (150 MHz, 298 K); Figure S10: Chemical structure, atom carbon position numbers and physical data for streptocarbazole B (SCZ B, <bold>4</bold>); Table S4: NMR data for streptocarbazole B (SCZ B, <bold>4</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S11: <sup>1</sup>H NMR spectrum of streptocarbazole B (SCZ B, <bold>4</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (600 MHz, 298 K); Figure S12: <sup>13</sup>C NMR spectrum of streptocarbazole B (SCZ B, <bold>4</bold>) in CD<sub>2</sub>Cl<sub>2</sub> (150 MHz, 298 K).</p><supplementary-material content-type="local-data" id="marinedrugs-17-00588-s001"><media xlink:href="marinedrugs-17-00588-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>J.L.-M., A.R.D.-M., J.E.P., and J.J.F. conceived and designed the experiments. L.C., A.R.D.-M., and J.J.F. conducted the isolation, culturing, phytochemical and spectral analysis of the chemical compounds. J.L.M., M.R.-B., J.E.P., I.A.-J., and I.S. contributed with the amoebicidal activity and their interpretation assays, Programmed Cell Death analysis and biological data compilation. All authors contributed equally to the final version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by PI18/01380 from Instituto de Salud Carlos III, Spain and RICET (RD16/0027/0001 project, from Programa Redes Tem&#x000e1;ticas de Investigaci&#x000f3;n Cooperativa), FIS (Ministerio Espa&#x000f1;ol de Salud, Madrid, Spain), FEDER and INTERREG-MAC/1.1b/042 (BIOTRANSFER2).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-17-00588"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>C.</given-names></name><name><surname>Mendez</surname><given-names>C.M.</given-names></name><name><surname>Salas</surname><given-names>J.A.</given-names></name></person-group><article-title>Indolocarbazole natural products: Occurrence, biosynthesis, and biological activity</article-title><source>Nat. Prod. Rep.</source><year>2006</year><volume>23</volume><fpage>1007</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1039/B601930G</pub-id><pub-id pub-id-type="pmid">17119643</pub-id></element-citation></ref><ref id="B2-marinedrugs-17-00588"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>H.</given-names></name><name><surname>Omura</surname><given-names>S.</given-names></name></person-group><article-title>Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine</article-title><source>J. Antibiot.</source><year>2009</year><volume>62</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/ja.2008.4</pub-id><pub-id pub-id-type="pmid">19132059</pub-id></element-citation></ref><ref id="B3-marinedrugs-17-00588"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanosik</surname><given-names>T.</given-names></name><name><surname>Rannug</surname><given-names>A.</given-names></name><name><surname>Rannug</surname><given-names>U.</given-names></name><name><surname>Whalstr&#x000f6;m</surname><given-names>N.</given-names></name><name><surname>Sl&#x000e4;tt</surname><given-names>J.</given-names></name></person-group><article-title>Chemistry and properties of Indolocarbazoles</article-title><source>Chem. Rev.</source><year>2018</year><volume>118</volume><fpage>9058</fpage><lpage>9128</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00186</pub-id><pub-id pub-id-type="pmid">30191712</pub-id></element-citation></ref><ref id="B4-marinedrugs-17-00588"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omura</surname><given-names>S.</given-names></name><name><surname>Iwai</surname><given-names>Y.</given-names></name><name><surname>Hirano</surname><given-names>A.</given-names></name><name><surname>Nakagawa</surname><given-names>A.</given-names></name><name><surname>Awaya</surname><given-names>J.</given-names></name><name><surname>Tsuchiya</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Masuma</surname><given-names>R.</given-names></name></person-group><article-title>A new alkaloid AM-2282 of <italic>Streptomyces</italic> origin. Taxonomy, fermentation, isolation and preliminary characterization</article-title><source>J. Antibiot.</source><year>1977</year><volume>30</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.30.275</pub-id><pub-id pub-id-type="pmid">863788</pub-id></element-citation></ref><ref id="B5-marinedrugs-17-00588"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamaoki</surname><given-names>T.</given-names></name><name><surname>Nomoto</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>I.</given-names></name><name><surname>Kato</surname><given-names>Y.</given-names></name><name><surname>Morimoto</surname><given-names>M.</given-names></name><name><surname>Tomita</surname><given-names>F.</given-names></name></person-group><article-title>Staurosporine, a potent inhibitor of phospholipid/Ca<sup>++</sup>dependent protein kinase</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1986</year><volume>135</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(86)90008-2</pub-id><pub-id pub-id-type="pmid">3457562</pub-id></element-citation></ref><ref id="B6-marinedrugs-17-00588"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrie</surname><given-names>A.M.</given-names></name><name><surname>Noble</surname><given-names>M.E.M.</given-names></name><name><surname>Tunnah</surname><given-names>P.</given-names></name><name><surname>Brown</surname><given-names>N.R.</given-names></name><name><surname>Johnson</surname><given-names>L.N.</given-names></name><name><surname>Endicott</surname><given-names>J.A.</given-names></name></person-group><article-title>Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2</article-title><source>Nat. Struct. Biol.</source><year>1997</year><volume>4</volume><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/nsb1097-796</pub-id><pub-id pub-id-type="pmid">9334743</pub-id></element-citation></ref><ref id="B7-marinedrugs-17-00588"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kase</surname><given-names>H.</given-names></name><name><surname>Iwahashi</surname><given-names>K.</given-names></name><name><surname>Nakanishi</surname><given-names>S.</given-names></name><name><surname>Matsuda</surname><given-names>Y.</given-names></name><name><surname>Yamada</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Murakata</surname><given-names>C.</given-names></name><name><surname>Sato</surname><given-names>A.</given-names></name><name><surname>Kaneko</surname><given-names>M.</given-names></name></person-group><article-title>K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1987</year><volume>30</volume><fpage>436</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(87)90293-2</pub-id></element-citation></ref><ref id="B8-marinedrugs-17-00588"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapley</surname><given-names>P.</given-names></name><name><surname>Lamballe</surname><given-names>F.</given-names></name><name><surname>Barbacid</surname><given-names>M.</given-names></name></person-group><article-title>K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">1312698</pub-id></element-citation></ref><ref id="B9-marinedrugs-17-00588"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Murakata</surname><given-names>C.</given-names></name><name><surname>Ashizawa</surname><given-names>T.</given-names></name><name><surname>Okabe</surname><given-names>M.</given-names></name><name><surname>Nakano</surname><given-names>H.</given-names></name></person-group><article-title>Induction of Mammalian DNA Topoisomerase I Mediated DNA Cleavage by Antitumor Indolocarbazole Derivatives</article-title><source>Biochemistry</source><year>1992</year><volume>31</volume><fpage>12069</fpage><lpage>12075</lpage><pub-id pub-id-type="doi">10.1021/bi00163a015</pub-id><pub-id pub-id-type="pmid">1333791</pub-id></element-citation></ref><ref id="B10-marinedrugs-17-00588"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welburn</surname><given-names>S.</given-names></name><name><surname>Macleod</surname><given-names>E.</given-names></name><name><surname>Figarella</surname><given-names>K.</given-names></name><name><surname>Duzensko</surname><given-names>M.</given-names></name></person-group><article-title>Programmed cell death in African trypanosomes</article-title><source>Parasitology</source><year>2006</year><volume>132</volume><issue>Suppl. 1</issue><fpage>S7</fpage><lpage>S18</lpage><pub-id pub-id-type="doi">10.1017/S0031182006000825</pub-id><pub-id pub-id-type="pmid">17018168</pub-id></element-citation></ref><ref id="B11-marinedrugs-17-00588"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Howe</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>K.</given-names></name></person-group><article-title>Staurosporine-induced programmed cell death in Blastocystis occurs independently of caspases and cathepsins and is augmented by calpain inhibition</article-title><source>Microbiology</source><year>2010</year><volume>156</volume><fpage>1284</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1099/mic.0.034025-0</pub-id><pub-id pub-id-type="pmid">20056704</pub-id></element-citation></ref><ref id="B12-marinedrugs-17-00588"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruges</surname><given-names>G.</given-names></name><name><surname>Betancourt</surname><given-names>M.</given-names></name><name><surname>March</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Mijares</surname><given-names>A.</given-names></name></person-group><article-title>Apoptotic-like activity of staurosporine in axenic cultures of <italic>Trypanosoma evansi</italic></article-title><source>Rev. Inst. Med. Trop.</source><year>2012</year><volume>54</volume><fpage>103</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1590/S0036-46652012000200008</pub-id></element-citation></ref><ref id="B13-marinedrugs-17-00588"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naula</surname><given-names>C.</given-names></name><name><surname>Parsons</surname><given-names>M.</given-names></name><name><surname>Mottram</surname><given-names>J.</given-names></name></person-group><article-title>Protein kinases as drug targets in trypanosomes and <italic>Leishmania</italic></article-title><source>Biochim. Biophys. Acta</source><year>2005</year><volume>1754</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2005.08.018</pub-id><pub-id pub-id-type="pmid">16198642</pub-id></element-citation></ref><ref id="B14-marinedrugs-17-00588"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>T.</given-names></name><name><surname>Bruges</surname><given-names>G.</given-names></name><name><surname>Meiwes</surname><given-names>A.</given-names></name><name><surname>Mogk</surname><given-names>S.</given-names></name><name><surname>Mudogo</surname><given-names>C.</given-names></name><name><surname>Duszenko</surname><given-names>M.</given-names></name></person-group><article-title>Staurosporine-Induced Cell Death in <italic>Trypanosoma brucei</italic> and the Role of Endonuclease G during Apoptosis</article-title><source>Open J. Apoptosis</source><year>2014</year><volume>3</volume><fpage>16</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.4236/ojapo.2014.32003</pub-id></element-citation></ref><ref id="B15-marinedrugs-17-00588"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>H.</given-names></name><name><surname>Koshino</surname><given-names>H.</given-names></name><name><surname>Kudo</surname><given-names>T.</given-names></name><name><surname>Onose</surname><given-names>R.</given-names></name><name><surname>Isono</surname><given-names>K.</given-names></name></person-group><article-title>A new inhibitor of protein kinase c, rk- 1409 (7-oxostaurosporine) I. Taxonomy and biological activity</article-title><source>J. Antibiot.</source><year>1992</year><volume>45</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.45.189</pub-id><pub-id pub-id-type="pmid">1556009</pub-id></element-citation></ref><ref id="B16-marinedrugs-17-00588"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Fredenhagen</surname><given-names>A.</given-names></name><name><surname>Hug</surname><given-names>P.</given-names></name><name><surname>Meyer</surname><given-names>T.</given-names></name></person-group><article-title>Further minor metabolites of Staurosporine produced by a <italic>Streptomyces longisporoflavus</italic> strain</article-title><source>J. Antibiot.</source><year>1996</year><volume>49</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.49.519</pub-id><pub-id pub-id-type="pmid">8698633</pub-id></element-citation></ref><ref id="B17-marinedrugs-17-00588"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Su</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Streptocarbazoles A and B, Two Novel Indolocarbazoles from the Marine-Derived Actinomycete Strain <italic>Streptomyces</italic> sp. FMA</article-title><source>Org. Lett.</source><year>2012</year><volume>14</volume><fpage>2422</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.1021/ol3008638</pub-id><pub-id pub-id-type="pmid">22519738</pub-id></element-citation></ref><ref id="B18-marinedrugs-17-00588"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartuche</surname><given-names>L.</given-names></name><name><surname>Sifaoui</surname><given-names>I.</given-names></name><name><surname>Cruz</surname><given-names>D.</given-names></name><name><surname>Reyes-Batlle</surname><given-names>M.</given-names></name><name><surname>Lopez-Arencibia</surname><given-names>A.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J.J.</given-names></name><name><surname>Diaz-Marrero</surname><given-names>A.R.</given-names></name><name><surname>Pi&#x000f1;ero</surname><given-names>J.E.</given-names></name><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name></person-group><article-title>Staurosporine from <italic>Streptomyces sanyensis</italic> activates Programmed Cell Death in <italic>Acanthamoeba</italic> via the mitochondrial pathway and presents low cytotoxicity levels to vertebrate cells</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>11651</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-48261-7</pub-id><pub-id pub-id-type="pmid">31406269</pub-id></element-citation></ref><ref id="B19-marinedrugs-17-00588"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taravaud</surname><given-names>A.</given-names></name><name><surname>Loiseau</surname><given-names>P.M.</given-names></name><name><surname>Pomel</surname><given-names>S.</given-names></name></person-group><article-title>In vitro evaluation of antimicrobial agents on <italic>Acanthamoeba</italic> sp. and evidence of a natural resilience to amphotericin B</article-title><source>Int. J. Parasitol. Drugs Drug Resist.</source><year>2017</year><volume>7</volume><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2017.09.002</pub-id><pub-id pub-id-type="pmid">28918001</pub-id></element-citation></ref><ref id="B20-marinedrugs-17-00588"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Davis</surname><given-names>S.</given-names></name><name><surname>Sifaoui</surname><given-names>I.</given-names></name><name><surname>Reyes-Batlle</surname><given-names>M.</given-names></name><name><surname>Viveros-Valdez</surname><given-names>E.</given-names></name><name><surname>Pi&#x000f1;ero</surname><given-names>J.E.</given-names></name><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J.J.</given-names></name><name><surname>D&#x000ed;az-Marrero</surname><given-names>A.R.</given-names></name></person-group><article-title>Anti-<italic>Acanthamoeba</italic> Activity of Brominated Sesquiterpenes from <italic>Laurencia johnstonii</italic></article-title><source>Mar. Drugs</source><year>2018</year><volume>16</volume><elocation-id>443</elocation-id><pub-id pub-id-type="doi">10.3390/md16110443</pub-id></element-citation></ref><ref id="B21-marinedrugs-17-00588"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name><name><surname>D&#x000ed;az-Marrero</surname><given-names>A.R.</given-names></name><name><surname>Cen-Pacheco</surname><given-names>F.</given-names></name><name><surname>Sifaoui</surname><given-names>I.</given-names></name><name><surname>Reyes-Batlle</surname><given-names>M.</given-names></name><name><surname>Souto</surname><given-names>M.L.</given-names></name><name><surname>Hern&#x000e1;ndez Daranas</surname><given-names>A.</given-names></name><name><surname>Pi&#x000f1;ero</surname><given-names>J.E.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J.J.</given-names></name></person-group><article-title>Evaluation of Oxasqualenoids from the Red Alga <italic>Laurencia viridis</italic> against <italic>Acanthamoeba</italic></article-title><source>Mar. Drugs</source><year>2019</year><volume>17</volume><elocation-id>420</elocation-id><pub-id pub-id-type="doi">10.3390/md17070420</pub-id><pub-id pub-id-type="pmid">31331002</pub-id></element-citation></ref><ref id="B22-marinedrugs-17-00588"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczanowski</surname><given-names>S.</given-names></name><name><surname>Sajid</surname><given-names>M.</given-names></name><name><surname>Reece</surname><given-names>S.E.</given-names></name></person-group><article-title>Evolution of apoptosis-like programmed cell death in unicellular protozoan parasites</article-title><source>Parasites Vectors</source><year>2011</year><volume>4</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1756-3305-4-44</pub-id><pub-id pub-id-type="pmid">21210995</pub-id></element-citation></ref><ref id="B23-marinedrugs-17-00588"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gani</surname><given-names>O.A.S.M.</given-names></name><name><surname>Engh</surname><given-names>R.A.</given-names></name></person-group><article-title>Protein kinase inhibition of clinically important staurosporine analogues</article-title><source>Nat. Prod. Rep.</source><year>2010</year><volume>27</volume><fpage>489</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1039/b923848b</pub-id><pub-id pub-id-type="pmid">20336234</pub-id></element-citation></ref><ref id="B24-marinedrugs-17-00588"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tanramluk</surname><given-names>D.</given-names></name></person-group><article-title>On the Origins of Enzyme Inhibitor Selectivity and Promiscuity: A Case of Study of Protein Kinase Binding to Staurosporine</article-title><source>Ph.D. Thesis</source><publisher-name>University of Cambridge</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2009</year></element-citation></ref><ref id="B25-marinedrugs-17-00588"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>B.H.</given-names></name><name><surname>Rose</surname><given-names>W.C.</given-names></name><name><surname>Vyas</surname><given-names>D.M.</given-names></name><name><surname>Matson</surname><given-names>J.A.</given-names></name><name><surname>Forenza</surname><given-names>S.</given-names></name></person-group><article-title>Discovery of antitumor indolocarbazoles: Rebeccamycin, NSC 655649, and fluoroindolocarbazoles</article-title><source>Curr. Med. Chem. Anticancer Agents</source><year>2002</year><volume>2</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.2174/1568011023354218</pub-id><pub-id pub-id-type="pmid">12678746</pub-id></element-citation></ref><ref id="B26-marinedrugs-17-00588"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>E.R.</given-names></name><name><surname>Belin</surname><given-names>L.</given-names></name><name><surname>Sancelme</surname><given-names>M.</given-names></name><name><surname>Prudhomme</surname><given-names>M.</given-names></name><name><surname>Ollier</surname><given-names>M.</given-names></name><name><surname>Rapp</surname><given-names>M.</given-names></name><name><surname>Sev&#x000e8;re</surname><given-names>D.</given-names></name><name><surname>Riou</surname><given-names>F.-F.</given-names></name><name><surname>Fabbro</surname><given-names>D.</given-names></name><name><surname>Meyer</surname><given-names>T.</given-names></name></person-group><article-title>Structure-activity relationships in a series of substituted indolocarbazoles: Topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties</article-title><source>J. Med. Chem.</source><year>1996</year><volume>39</volume><fpage>4471</fpage><lpage>4477</lpage><pub-id pub-id-type="doi">10.1021/jm9603779</pub-id><pub-id pub-id-type="pmid">8893841</pub-id></element-citation></ref><ref id="B27-marinedrugs-17-00588"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinelli</surname><given-names>M.A.</given-names></name></person-group><article-title>Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates and serendipitous discoveries</article-title><source>Med. Res. Rev.</source><year>2019</year><volume>39</volume><fpage>1294</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1002/med.21546</pub-id><pub-id pub-id-type="pmid">30456874</pub-id></element-citation></ref><ref id="B28-marinedrugs-17-00588"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhaduri</surname><given-names>S.</given-names></name><name><surname>Ranjan</surname><given-names>N.</given-names></name><name><surname>Arya</surname><given-names>D.P.</given-names></name></person-group><article-title>An overview of recent advances in duplex DNA recognition by small molecules</article-title><source>Beilstein J. Org. Chem.</source><year>2018</year><volume>14</volume><fpage>1051</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.3762/bjoc.14.93</pub-id><pub-id pub-id-type="pmid">29977379</pub-id></element-citation></ref><ref id="B29-marinedrugs-17-00588"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Bra&#x000f1;a</surname><given-names>A.F.</given-names></name><name><surname>Salas</surname><given-names>A.P.</given-names></name><name><surname>Rohr</surname><given-names>J.</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name><name><surname>Salas</surname><given-names>J.A.</given-names></name></person-group><article-title>Combinatorial Biosynthesis of Antitumor Indolocarbazole Compounds</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>46</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407809102</pub-id></element-citation></ref><ref id="B30-marinedrugs-17-00588"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>J.A.</given-names></name><name><surname>Long</surname><given-names>B.H.</given-names></name><name><surname>Catino</surname><given-names>J.J.</given-names></name><name><surname>Bradner</surname><given-names>W.T.</given-names></name><name><surname>Tomita</surname><given-names>K.</given-names></name></person-group><article-title>Production and biological activity of rebeccamycin, a novel antitumor agent</article-title><source>J. Antibiot. (Tokyo)</source><year>1987</year><volume>40</volume><fpage>668</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.40.668</pub-id><pub-id pub-id-type="pmid">3112080</pub-id></element-citation></ref><ref id="B31-marinedrugs-17-00588"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Martinez</surname><given-names>C.</given-names></name><name><surname>Shih</surname><given-names>C.</given-names></name><name><surname>Faul</surname><given-names>M.M.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Paal</surname><given-names>M.</given-names></name><name><surname>Somoza</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Kumrich</surname><given-names>C.A.</given-names></name><name><surname>Winneroski</surname><given-names>L.L.</given-names></name><name><surname>Xun</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2003</year><volume>13</volume><fpage>3835</fpage><lpage>3839</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(03)00791-1</pub-id><pub-id pub-id-type="pmid">14552791</pub-id></element-citation></ref><ref id="B32-marinedrugs-17-00588"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Robles</surname><given-names>A.</given-names></name><name><surname>Salazar-Villatoro</surname><given-names>L.</given-names></name><name><surname>Oma&#x000f1;a-Molina</surname><given-names>M.</given-names></name><name><surname>Reyes-Batlle</surname><given-names>M.</given-names></name><name><surname>Mart&#x000ed;n-Navarro</surname><given-names>C.M.</given-names></name><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name></person-group><article-title>Morphological Features and In Vitro Cytopathic Effect of <italic>Acanthamoeba griffini</italic> Trophozoites Isolated from a Clinical Case</article-title><source>J. Parasitol. Res.</source><year>2014</year><volume>2014</volume><fpage>256310</fpage><pub-id pub-id-type="doi">10.1155/2014/256310</pub-id><pub-id pub-id-type="pmid">25313337</pub-id></element-citation></ref><ref id="B33-marinedrugs-17-00588"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>J.</given-names></name><name><surname>Ingram</surname><given-names>P.R.</given-names></name><name><surname>Henriquez</surname><given-names>F.L.</given-names></name><name><surname>Roberts</surname><given-names>C.W.</given-names></name></person-group><article-title>Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba</article-title><source>J. Clin. Microbiol.</source><year>2005</year><volume>43</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.2.629-634.2005</pub-id><pub-id pub-id-type="pmid">15695656</pub-id></element-citation></ref><ref id="B34-marinedrugs-17-00588"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name><name><surname>Khan</surname><given-names>N.A.</given-names></name><name><surname>Walochnik</surname><given-names>J.</given-names></name></person-group><article-title>An update on <italic>Acanthamoeba</italic> keratitis: Diagnosis, pathogenesis and treatment</article-title><source>Parasite</source><year>2015</year><volume>22</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1051/parasite/2015010</pub-id><pub-id pub-id-type="pmid">25687209</pub-id></element-citation></ref><ref id="B35-marinedrugs-17-00588"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo-Morales</surname><given-names>J.</given-names></name><name><surname>Kliescikova</surname><given-names>J.</given-names></name><name><surname>Martinez-Carretero</surname><given-names>E.</given-names></name><name><surname>De Pablos</surname><given-names>L.M.</given-names></name><name><surname>Profotova</surname><given-names>B.</given-names></name><name><surname>Nohynkova</surname><given-names>E.</given-names></name><name><surname>Osuna</surname><given-names>A.</given-names></name><name><surname>Valladares</surname><given-names>B.</given-names></name></person-group><article-title>Glycogen phosphorylase in <italic>Acanthamoeba</italic> spp.: Determining the role of the enzyme during the encystment process using RNA interference</article-title><source>Eukaryot. Cell</source><year>2008</year><volume>7</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1128/EC.00316-07</pub-id><pub-id pub-id-type="pmid">18223117</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-17-00588-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structures of indolocarbazole (ICZs) metabolites isolated from cultures of <italic>Streptomyces sanyensis</italic> PBLC04 strain.</p></caption><graphic xlink:href="marinedrugs-17-00588-g001"/></fig><fig id="marinedrugs-17-00588-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of 7OSTS (<bold>2</bold>) on the cyst of <italic>A. castellanii</italic> Neff at 10 &#x000b5;M (<bold>A</bold>), 2.6 &#x000b5;M (<bold>B</bold>), 0.65 &#x000b5;M (<bold>C</bold>), and negative control (<bold>D</bold>). All images (10&#x000d7;) are representative of the population of treated amoeba, and are based on Live Cell Imaging Microscope EVOS FL Cell Imaging System.</p></caption><graphic xlink:href="marinedrugs-17-00588-g002"/></fig><fig id="marinedrugs-17-00588-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Effect of the IC<sub>90</sub> concentration of 7OSTS (<bold>2</bold>) on the chromatin condensation at 24 h (<bold>A</bold>) and negative control (<bold>B</bold>) (overlay channels). All images (20&#x000d7;) are representative of the population of treated amoeba and are based on Live Cell Imaging Microscope EVOS FL Cell Imaging System.</p></caption><graphic xlink:href="marinedrugs-17-00588-g003"/></fig><fig id="marinedrugs-17-00588-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Effect on the mitochondrial potential in amoeba treated with the IC<sub>90</sub> of 7PSTS for 24&#x02009;h (<bold>A</bold>) compared with the negative control (<bold>B</bold>) (overlay channels). JC-1 dye remained in the cytoplasm in its monomeric form, green fluorescence, and indicates the collapse of mitochondrial potential (<bold>A</bold>). In negative control (<bold>B</bold>) JC-1 dye accumulates in the mitochondria of healthy cells as aggregates (red fluorescence). All images (20&#x000d7;) are representative of the population of treated amoeba, and are based on Live Cell Imaging Microscope EVOS FL Cell Imaging System.</p></caption><graphic xlink:href="marinedrugs-17-00588-g004"/></fig><fig id="marinedrugs-17-00588-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>ATP measurement assay with negative control and 7OSTS (<bold>2</bold>).</p></caption><graphic xlink:href="marinedrugs-17-00588-g005"/></fig><fig id="marinedrugs-17-00588-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Permeabilization of the <italic>A. castellanii</italic> Neff plasmatic membrane to SYTOX<sup>&#x000ae;</sup> Green dye caused by addition of IC<sub>90</sub> of 7OSTS (<bold>2</bold>) (<bold>A</bold>) comparing with the negative control (<bold>B</bold>) (overlay channels). All images (20&#x000d7;) are representative of the population of treated amoeba, and are based on Live Cell Imaging Microscope EVOS FL Cell Imaging System.</p></caption><graphic xlink:href="marinedrugs-17-00588-g006"/></fig><fig id="marinedrugs-17-00588-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Commercial ICZs: rebeccamycin (<bold>5</bold>), K252c (<bold>6</bold>), and arcyriaflavin A (<bold>7</bold>).</p></caption><graphic xlink:href="marinedrugs-17-00588-g007"/></fig><fig id="marinedrugs-17-00588-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>3D Chemical structures for (ICZs) metabolites isolated from <italic>Streptomyces sanyensis</italic> cultures. Top and perpendicular views to the indol system. Red arrows indicate the interaction sites of stauroporine (STS, <bold>1</bold>) with protein kinase type CDK2 models. Minimized structures were obtained using Maestro, version 10.2, Schr&#x000f6;dinger, LLC, New York, NY, 2015.</p></caption><graphic xlink:href="marinedrugs-17-00588-g008"/></fig><table-wrap id="marinedrugs-17-00588-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00588-t001_Table 1</object-id><label>Table 1</label><caption><p>Effects of ICZ metabolites isolated from <italic>Streptomyces sanyensis</italic> against <italic>Acanthamoeba</italic> species. IC<sub>50</sub> are reported in &#x000b5;M concentrations (Mean concentration &#x000b1; SD). * Reference compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>A. castellanii</italic> Neff</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. griffini</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. polyphaga</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">STS (<bold>1</bold>) [<xref rid="B18-marinedrugs-17-00588" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 &#x000b1; 0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97&#x000b1; 0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">2.25 &#x000b1; 0.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7OSTS (<bold>2</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 &#x000b1; 0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 &#x000b1; 0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">5.51 &#x000b1; 0.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02019;D4&#x02019;OSTS (<bold>3</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.53 &#x000b1; 0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">23.86 &#x000b1; 0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ICZ B (<bold>4</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.83 &#x000b1; 2.60</td><td align="center" valign="middle" rowspan="1" colspan="1">14.51 &#x000b1;0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rebeccamycin (<bold>5</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.37 &#x000b1; 0.23</td><td align="center" valign="middle" rowspan="1" colspan="1">5.02 &#x000b1; 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">7.47 &#x000b1; 0.61</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K252c (<bold>6</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.17 &#x000b1; 0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">2.25 &#x000b1; 0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">5.59 &#x000b1; 0.34</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arcyriaflavin A (<bold>7</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.32 &#x000b1; 0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">7.53 &#x000b1; 1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">7.59 &#x000b1; 0.73</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chlorhexidine *</td><td align="center" valign="middle" rowspan="1" colspan="1">3.02 &#x000b1; 0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">3.73 &#x000b1; 0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">4.76 &#x000b1; 0.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 &#x000b1; 0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.10 &#x000b1; 2.21</td></tr></tbody></table></table-wrap><table-wrap id="marinedrugs-17-00588-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00588-t002_Table 2</object-id><label>Table 2</label><caption><p>Toxicity of compounds <bold>1</bold>&#x02013;<bold>4</bold> against murine macrophage J774A.1 (CC<sub>50</sub>) measured by alamarBlue<sup>&#x000ae;</sup> assay; and CC<sub>50</sub> are reported in &#x000b5;M concentrations (Mean concentration &#x000b1; SD). *Reference compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Macrophage J774A.1 CC<sub>50</sub> (&#x000b5;M)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">STS (<bold>1</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.74 &#x000b1; 0.72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7OSTS (<bold>2</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.20 &#x000b1; 1.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02019;D4&#x02019;OSTS (<bold>3</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ICZ B (<bold>4</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chlorhexidine *</td><td align="center" valign="middle" rowspan="1" colspan="1">7.40 &#x000b1; 0.39</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voriconazole *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.56 &#x000b1; 0.77</td></tr></tbody></table></table-wrap></floats-group></article>